Codexis Highlights RNA Medicine Focus in Q4 Earnings Call

Company emphasizes progress on enzymatic siRNA manufacturing platform, growing commercial engagement, and stronger liquidity position.

Mar. 11, 2026 at 10:22pm

Got story updates? Submit your updates here. ›

Codexis (NASDAQ:CDXS) used its fourth-quarter and full-year 2025 earnings call to highlight progress behind its strategic focus on RNA medicines, with management emphasizing technical milestones for its enzymatic siRNA manufacturing platform, growing commercial engagement, and a stronger liquidity position following a technology transfer agreement with Merck.

Why it matters

Codexis is positioning itself as a leader in the rapidly growing field of RNA medicine production, with its proprietary ECO Synthesis platform aiming to address the increasing demand for siRNA medicines that current technologies may struggle to meet. The company's progress on manufacturing capabilities, commercial partnerships, and financial position could help drive further adoption of its innovative enzymatic approach.

The details

Key highlights from the earnings call include: Codexis' ECO Synthesis platform achieving technical milestones like producing a 3-kilogram batch of siRNA using the company's ligase enzyme; progress on building a supply chain and achieving quality certifications to support ECO Synthesis; plans to retrofit a new GMP facility to enable clinical and commercial production; growing commercial engagement with 55 opportunities across 40 companies, including a low seven-figure contract for preclinical supply; and a technology transfer agreement with Merck that provided $38 million in non-dilutive capital.

  • Codexis modernized its non-GMP production capability and achieved ISO 9001 certification in the first quarter of 2026.
  • Codexis expects to begin construction on its new GMP facility in the second half of 2026 and have it fully operational by the end of 2027.
  • The low seven-figure contract with an emerging biotech company is expected to be completed over the next 12 months.

The players

Codexis, Inc.

A leading protein engineering company focused on the development of innovative enzyme solutions for pharmaceutical, food and beverage, and specialty chemical applications. The company's proprietary directed evolution platform, CodeEvolver®, enables the rapid identification and optimization of enzymes with enhanced activity, selectivity and stability.

Dr. Alison Moore

President and CEO of Codexis.

Britton Jimenez

Senior Vice President of Sales and Marketing at Codexis.

Georgia Erbez

Chief Financial Officer and Chief Business Officer at Codexis.

Merck

A large pharmaceutical company that Codexis has a technology transfer agreement with.

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident (San Francisco Chronicle)

“Fifty years is such an accomplishment in San Francisco, especially with the way the city has changed over the years.”

— Gordon Edgar, grocery employee (Instagram)

What’s next

Codexis expects to begin construction on its new GMP facility in the second half of 2026 and have it fully operational by the end of 2027, supporting adoption of ECO Synthesis and enabling the company to serve customers with GMP siRNA.

The takeaway

Codexis is positioning itself as a leader in the rapidly growing field of RNA medicine production, with its proprietary ECO Synthesis platform aiming to address the increasing demand for siRNA medicines that current technologies may struggle to meet. The company's progress on manufacturing capabilities, commercial partnerships, and financial position could help drive further adoption of its innovative enzymatic approach.